Akèy › Limfom Difize Gwo Selil B › Kalifòni › Los Angeles
Etid klinik pou Limfom Difize Gwo Selil B nan Los Angeles, CA
17 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan ak bò kote Los Angeles (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Ap rekriteFaz 2
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles, Los Angeles
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Ap rekriteFaz 2
- Cedars-Sinai Medical Center, Los Angeles
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Ap rekriteFaz 3
- Cedars-Sinai Medical Center ( Site 0115), Los Angeles
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Ap rekriteFaz 3
- David Geffen School of Medicine at UCLA, Los Angeles
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
- University of California, Los Angeles (UCLA) - Medical Center, Los Angeles
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Ap rekriteFaz 1/2
- Children's Hospital Los Angeles ( Site 1006), Los Angeles
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Ap rekriteFaz 2
- Valkyrie Clinical Trials, Los Angeles
A Study of ARC-02 in B-cell NHL
Ap rekriteFaz 1
- Start Cala, Los Angeles
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles (UCLA) Medical Center, Los Angeles
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Ap rekriteFaz 1
- Cedars-Sinai Medical Center, Los Angeles
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- Valkyrie Clinical Trials, Los Angeles
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles (UCLA), Los Angeles
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ap rekriteFaz 1
- START Los Angele, Los Angeles
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Ap rekriteFaz 1/2
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Ap rekriteFaz 1/2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Ap rekriteFaz 2
- Cedars Sinai Medical Center, Los Angeles
A Study of NX-1607 in Adults With Advanced Malignancies
Ap rekriteFaz 1
- University of Southern California, Los Angeles
Etid Limfom Difize Gwo Selil B nan lòt vil
- New York City, NY21 etid
- Baldwin Park, CA19 etid
- Chicago, IL18 etid
- Houston, TX17 etid
- Boston, MA16 etid
- Milwaukee, WI16 etid
- Nashville, TN15 etid
- Portland, OR15 etid
- Philadelphia, PA15 etid
- Durham, NC14 etid
- Dallas, TX13 etid
- Seattle, WA12 etid
Lòt etid nan Los Angeles
- Kansè Poumon ki pa ti selil87 etid
- Kansè (tout kalite)73 etid
- Kansè nan tete72 etid
- Kansè pwostat61 etid
- Kansè kolorektal59 etid
- Kansè Metastatik57 etid
- Kansè ovè50 etid
- Kansè poumon45 etid
- Karsinòm selil skuamèz tèt ak kou42 etid
- Kansè pankreyas35 etid
- Kansè Endomèt34 etid
- Melanom34 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.